Cabergoline therapy for prolactinomas: Is valvular heart disease a real safety concern?

Expert Review of Cardiovascular Therapy

Volumn 8, Issue 1, 2010, Pages 49-54

  Vallette, Sophie ^a   Serri, Karim ^b   Serri, Omar ^a  

^a NOTRE DAME HOSPITAL   (Canada)

^b HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

Author keywords

cabergoline; cardiac valve disease; hyperprolactinemia; prolactinoma; valvulopathy

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE 2 RECEPTOR; PERGOLIDE; QUINAGOLIDE; SEROTONIN RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; ERGOLINE DERIVATIVE;

CLINICAL PROTOCOL; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG SUBSTITUTION; ECHOCARDIOGRAPHY; FOLLOW UP; GASTROINTESTINAL DISEASE; HUMAN; LOW DRUG DOSE; LUNG FIBROSIS; PARKINSON DISEASE; PROLACTINOMA; RECEPTOR AFFINITY; RETROPERITONEAL FIBROSIS; REVIEW; SOMNOLENCE; TREATMENT DURATION; TRICUSPID VALVE REGURGITATION; VALVULAR HEART DISEASE; ADULT; ARTICLE; CASE CONTROL STUDY; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DRUG POTENTIATION; FEMALE; HYPOPHYSIS TUMOR; MALE; MIDDLE AGED;

ADULT; CASE-CONTROL STUDIES; CLINICAL TRIALS AS TOPIC; DOPAMINE AGONISTS; ERGOLINES; FEMALE; HEART VALVE DISEASES; HUMANS; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; PROLACTINOMA; RECEPTORS, DOPAMINE D2;

EID: 77949538152     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.09.167     Document Type: Review

References (24)

1. Serri O. Progress in the management of hyperprolactinemia. N. Engl. J. Med. 331, 942-944 (1994).
2. Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocr. Rev. 27, 485-534 (2006).
3. Molitch ME. The cabergoline-resistant prolactinoma patient: new challenges. J. Clin. Endocrinol. Metab. 93:4643-4645(2008).
4. Cawood TJ, Bridgman P, Hunter L, Cole D. Low-dose cabergoline causing valvular heart disease in a patient treated for prolactinoma. Intern. Med. J. 39, 266-267 (2009).
5. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N. Engl. J. Med. 356, 39-46 (2007).
6. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N. Engl. J. Med. 356, 29-38 (2007).
7. Simonis G, Fuhrmann JT, Strasser RH. Meta-analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agonists. Mov. Disord. 22, 1936-1942 (2007).
8. Roth BL. Drugs and valvular heart disease. N. Engl. J. Med. 356, 6-9 (2007).
9. Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol. 6, 826-829 (2007).
10. Bogazzi F, Manetti L, Raffaelli V, Lombardi M, Rossi G, Martino E. Cabergoline therapy and the risk of cardiac valve regurgitation in patients with hyperprolactinemia: a meta-analysis from clinical studies. J. Endocrinol. Invest. 31, 1119-1123 (2008).
11. Kars M, Pereira AM, Bax JJ, Romijn JA. Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required. Eur. J. Endocrinol. 159, 363-367 (2008).
12. Sherlock M, Toogood AA, Steeds R. Dopamine agonist therapy for hyperprolactinaemia and cardiac valve dysfunction; a lot done but much more to do. Heart 95, 522-523 (2009).
13. Bogazzi F, Buralli S, Manetti L et al. Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia. Int. J. Clin. Pract. 62(12), 1864-1869 (2008).
14. Lancellotti P, Livadariu E, Markov M et al. Cabergoline and the risk of valvular lesions in endocrine disease. Eur. J. Endocrinol. 159(1), 1-5 (2008).
15. Colao A, Galderisi M, Di SA et al. Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. J. Clin. Endocrinol. Metab. 93, 3777-3784 (2008).
16. Kars M, Delgado V, Holman ER et al. Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. J. Clin. Endocrinol. Metab. 93, 3348-3356 (2008).
17. Vallette S, Serri K, Rivera J et al. Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary 12, 153-157 (2009).
18. Wakil A, Rigby AS, Clark AL, Kallvikbacka-Bennett A, Atkin SL. Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease. Eur. J. Endocrinol. 159, R11-R14 (2008).
19. Herring N, Szmigielski C, Becher H, Karavitaki N, Wass JA. Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clin. Endocrinol. (Oxford) 70, 104-108 (2009).
20. Devin JK, Lakhani VT, Byrd BF, III, Blevins LS Jr. Prevalence of valvular heart disease in a cohort of patients taking cabergoline for management of hyperprolactinemia. Endocr. Pract. 14, 672-677 (2008).
21. Zoghbi WA, Enriquez-Sarano M, Foster E et al. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J. Am. Soc. Echocardiogr. 16, 777-802 (2003).
22. Singh JP, Evans JC, Levy D et al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Fra mingham Hea rt Study). Am. J. Cardiol. 83, 897-902 (1999).
23. Steiger M, Jost W, Grandas F, Van CG. Risk of valvular heart disease associated with the use of dopamine agonists in Parkinson's disease: a systematic review. J. Neural Transm. 116, 179-191 (2009).
24. Ono M, Miki N, Kawamata T et al. Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. J. Clin. Endocrinol. Metab. 93, 4721-4727 (2008).